The Endometrial Receptivity Analysis (ERA) promised to solve one of IVF's most frustrating problems: perfectly good embryos failing to implant because the uterine lining was not ready to receive them. By biopsying the endometrium and analyzing gene expression, the ERA identifies your personal "window of implantation" so transfer timing can be adjusted.
It was a compelling idea. The evidence, however, has become more complicated.
How ERA Works
The ERA test, developed by Igenomix (now Vitrolife), analyzes the expression of 248 genes in a small endometrial biopsy sample. An algorithm classifies the endometrium as "receptive," "pre-receptive," or "post-receptive" at the time of biopsy.
The test is performed during a mock cycle — you take the same medications as a real FET but instead of an embryo transfer, a thin catheter takes a small tissue sample. Results return in about 2 weeks with a personalized transfer timing recommendation.
What the Latest Evidence Shows
The pivotal ERA-RCT trial, published in 2022 in The Lancet, was a multicenter randomized controlled trial involving over 750 patients with recurrent implantation failure. The result was sobering: personalized embryo transfer based on ERA results did not significantly improve live birth rates compared to standard timing.
This does not mean ERA is useless — but it significantly narrows who might benefit:
| Patient Group | ERA Benefit? | Evidence Level |
|---|---|---|
| First IVF cycle | No evidence of benefit | Strong (ERA-RCT) |
| 1-2 failed transfers | Unlikely beneficial | Moderate |
| 3+ failed euploid transfers | Possibly beneficial | Weak/observational |
| Known endometrial issues | May inform treatment | Case-by-case |
Cost Breakdown
The ERA test itself costs approximately $800-$1,200. But the total cost is higher when you include the mock cycle required to perform it:
- Mock cycle medications (estrogen + progesterone): $200-$500
- Monitoring ultrasounds: $300-$600
- Biopsy procedure: $500-$800
- ERA lab analysis: $800-$1,200
- Total: $1,800-$3,100
Plus the time cost: a mock cycle adds 4-6 weeks before your actual transfer.
Alternatives and Newer Tests
EMMA and ALICE: Often bundled with ERA, these tests assess the endometrial microbiome (EMMA) and screen for chronic endometritis (ALICE). The endometritis screening has stronger clinical support — chronic endometritis is a treatable cause of implantation failure that responds to targeted antibiotics.
ReceptivaDx: Tests for BCL6 protein, a biomarker for endometriosis. Elevated BCL6 may indicate silent endometriosis affecting implantation. Some clinics use this as an alternative or complement to ERA.
Questions to Ask Your RE
- Given the ERA-RCT results, do you still recommend ERA for my situation?
- How many failed transfers have I had with euploid embryos specifically?
- Would testing for chronic endometritis (via biopsy or hysteroscopy) be a more evidence-based first step?
- Do you offer EMMA/ALICE or ReceptivaDx as alternatives?
The Bottom Line
ERA was a promising concept that did not survive rigorous testing for the general IVF population. It may still have a narrow role for patients with multiple failed transfers of genetically normal embryos, where every other factor has been evaluated. But for most patients, the $2,000-$3,000 and 4-6 weeks of delay are better invested elsewhere in their treatment plan. Ask your RE to walk through the ERA-RCT data and explain why they do or do not recommend it for your specific case.
Related Reading
Explore More Resources
Track Your Cycle
OPK comparisons, BBT charts, and timing guides for every cycle type.
FertileStart →Optimize Your Body
Evidence-based supplements, nutrition plans, and lifestyle changes for fertility.
LifeFertile →The Full Picture
Your central hub for fertility news, research updates, and getting started.
HowToHaveABaby →